Normunity

Biotech · Private

T-cell engager bispecific antibodies targeting novel tumor antigens for solid cancers

normunity.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
11
0 granted · 11 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2659Blue Marlin Therapeutics, Inc.—$100K
2660CINDER BIOLOGICAL, INC.—$100K
2661Nano Pharmasolutions Inc.—$75K
2662Normunity——
2663UNIVERSAL CELLS, INC.—$60K
2664ISPIN, INC.——
2665Path BioAnalytics, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 11
  • ANTI-LY6K Antibodies And Methods Of Useapplication
  • ANTI-LY6K Antibody-drug Conjugates And Methods Of Useapplication
  • ANTI-KLK6 Antibodies And Methods Of Useapplication
  • ANTI-LY6K Antibodies And Methods Of Useapplication
  • ANTI-LY6K Antibodies And Methods Of Useapplication
  • ANTI-PLA2G10 Antibodies And Methods Of Useapplication
  • ANTI-LY6K Antibodies And Methods Of Useapplication
  • ANTI-KLK6 Antibodies And Methods Of Useapplication
  • ANTI-LY6K Antibodies And Methods Of Useapplication
  • ANTI-LY6K Antibodies And Methods Of Useapplication
  • ANTI-PLA2G10 Antibodies And Methods Of Useapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.